{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:57:50Z","timestamp":1794023870633,"version":"4.8.0"},"reference-count":52,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2023,6,3]]},"DOI":"10.1080\/03007995.2023.2214046","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:47:08Z","timestamp":1684482428000},"page":"833-842","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany"],"prefix":"10.1080","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7783-5926","authenticated-orcid":false,"given":"Nanna","family":"Nyholm","sequence":"first","affiliation":[{"name":"LEO Pharma AS","place":["Ballerup, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3138-5607","authenticated-orcid":false,"given":"Henrik","family":"Schnack","sequence":"additional","affiliation":[{"name":"EY","place":["Frederiksberg, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-5186","authenticated-orcid":false,"given":"Anne","family":"Dan\u00f8","sequence":"additional","affiliation":[{"name":"EY","place":["Frederiksberg, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-6578","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Skowron","sequence":"additional","affiliation":[{"name":"H\u00f4pitaux Dr\u00f4me Nord","place":["Romans-sur-Is\u00e8re, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183415"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S169389"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03372.x"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.365"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00117"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15539"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-35"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3114"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S286312"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13715"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00544-6"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2014.2403"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub2"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15277"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112297"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15340"},{"issue":"6","key":"e_1_3_6_24_1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/ddg.14508","article-title":"German S3\u2010guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm \u2013 part 1: treatment goals and treatment recommendations","volume":"19","author":"Nast A","year":"2021","unstructured":"Nast A, Altenburg A, Augustin M, et\u00a0al. German S3\u2010guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm \u2013 part 1: treatment goals and treatment recommendations. J Dtsch Dermatol Ges. 2021;19(6):934.","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S367744"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1743811"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00647-0"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19866"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00760-8"},{"key":"e_1_3_6_31_1","unstructured":"ABDATA Pharma-Daten-Service. Pharmaceutical manufacturer prices in Germany. 2023."},{"key":"e_1_3_6_32_1","unstructured":"National Health Insurance Agency (AMELI). Pharmaceutical retail prices in France. 2023."},{"key":"e_1_3_6_33_1","unstructured":"European Medicines Agency. Taltz: summary of product characteristics [Internet]. 2020 [cited 2022 Dec 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taltz-epar-product-information_en.pdf"},{"key":"e_1_3_6_34_1","unstructured":"European Medicines Agency. Bimzelx\u00ae: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bimzelx-epar-product-information_en.pdf"},{"key":"e_1_3_6_35_1","unstructured":"European Medicines Agency. Cosentyx\u00ae: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cosentyx-epar-product-information_en.pdf"},{"key":"e_1_3_6_36_1","unstructured":"European Medicines Agency. Enbrel\u00ae: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enbrel-epar-product-information_en.pdf"},{"key":"e_1_3_6_37_1","unstructured":"European Medicines Agency. Hulio\u00ae: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/hulio-epar-product-information_en.pdf"},{"key":"e_1_3_6_38_1","unstructured":"European Medicines Agency. Kyntheum\u00ae: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kyntheum-epar-product-information_en.pdf"},{"key":"e_1_3_6_39_1","unstructured":"European Medicines Agency. SkyriziTM: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/skyrizi-epar-product-information_en.pdf"},{"key":"e_1_3_6_40_1","unstructured":"European Medicines Agency. Stelara\u00ae: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/stelara-epar-product-information_en.pdf"},{"key":"e_1_3_6_41_1","unstructured":"European Medicines Agency. Tremfya\u00ae: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tremfya-epar-product-information_en.pdf"},{"key":"e_1_3_6_42_1","unstructured":"European Medicines Agency. Cimzia\u00ae: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cimzia-epar-product-information_en.pdf"},{"key":"e_1_3_6_43_1","unstructured":"European Medicines Agency. Ilumetri\u00ae: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ilumetri-epar-product-information_en.pdf"},{"key":"e_1_3_6_44_1","unstructured":"European Medicines Agency. Zessly\u00ae: summary of product characteristics [Internet]. 2022 [cited 2022 Dec 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zessly-epar-product-information_en.pdf"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15288"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00722-y"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1793891"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1970953"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0251-4"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1362413"},{"issue":"8","key":"e_1_3_6_51_1","first-page":"228424031882228","article-title":"Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy","volume":"2019","author":"Ravasio R","year":"2019","unstructured":"Ravasio R, Antonelli S, Maiorino A, et\u00a0al. Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy. Glob Reg Health Technol Assess. 2019;2019(8):228424031882228.","journal-title":"Glob Reg Health Technol Assess"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16809"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00598-4"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2023.2214046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T11:35:46Z","timestamp":1738409746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2023.2214046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,3]]}},"alternative-id":["10.1080\/03007995.2023.2214046"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2023.2214046","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}